Robin Carhart-Harris
Ralph Metzner Distinguished Professor
Data updated
Research Footprint
Robin Carhart-Harris appears in 219 tracked papers (2010–2026), most studied alongside Psilocybin, LSD and DMT, across Neuroimaging & Brain Measures, Depressive Disorders and Anxiety Disorders.
Most-cited paper: Psilocybin with psychological support for treatment-resistant depression: an open-label feasibility study (1520 citations).
Frequent co-authors: David Nutt, David Erritzoe and Leor Roseman.
Publication Landscape
How the 219 papers Blossom tracks for Robin Carhart-Harris line up by year, topic, and journal. These are the psychedelic-relevant papers in Blossom's records as of July 2026, not a complete bibliography.
How has Robin Carhart-Harris's publishing grown?
SourcedTracked papers by publication year; 3 earlier papers published before 2012. Click a year for the running total.
Don't read as total output: only the 219 of 219 tracked papers with a recorded publication date are counted, and these are the psychedelic-relevant papers Blossom tracks, not a complete bibliography. The current year is still filling in.
What does Robin Carhart-Harris publish on?
SourcedTracked papers per topic. Orange marks the largest research focus.
Don't read shares as adding to 100%: a paper tagged with several topics counts once per topic. These are the psychedelic-relevant papers Blossom tracks, not a complete bibliography.
Where does Robin Carhart-Harris publish?
SourcedTracked papers per journal. Orange marks the most-used journal.
Counts the journal recorded on each tracked paper; preprints and papers with no journal on file are not shown. These are the psychedelic-relevant papers Blossom tracks, not a complete bibliography.
Background & Research
Robin Carhart-Harris is a prominent British psychopharmacologist known for his pioneering research in psychedelic science. He currently serves as the Ralph Metzner Distinguished Professor at the University of California, San Francisco (UCSF) and is the Founding Director of the UCSF Neuroscape Psychedelics Division. Previously, he founded the Centre for Psychedelic Research at Imperial College London, the first of its kind in the world. His work focuses on the brain mechanisms and therapeutic potential of substances like psilocybin, LSD, MDMA, and DMT.
Key Impact
Pioneering researcher in brain imaging of psychedelics and founding director of the UCSF Neuroscape Psychedelics Division.
Collaboration Network
174 collaborators· click a node to visit their profile
Full network →Collaboration Network
See Robin Carhart-Harris's full collaboration network, shared papers, and research connections.
Compounds
Topics
Top Collaborators
Top Collaborators
Unlock clinical summaries, full texts, and related trial mapping.
Affiliations
Institutions, companies, and organisations Robin Carhart-Harris is associated with.
University of California, San Francisco
academicRalph Metzner Distinguished Professor
University of California, San Francisco (UCSF) hosts major psychedelic research activity through the Translational Psychedelic Research Program (TrPR), Neuroscape Psychedelics Division, and psychiatry-led clinical research on psychedelic-assisted therapies.
View stakeholder →Imperial College London
academicFounder, Centre for Psychedelic Research
The Centre for Psychedelic Research, led by Professor David Nutt and Dr. David Erritzoe, focuses heavily on the action of psychedelic drugs in the brain and their clinical utility as aides to psychotherapy. Thanks to their extensive neuroimaging studies, this group has proposed vital mechanisms for how psychedelics work, including the Entropic Brain Theory and REBUS (RElaxed Beliefs Under Psychedelics).
View stakeholder →Entropy Neurodynamics
Public BiotechChair, Scientific Advisory Board
Entropy Neurodynamics Limited (formerly Tryptamine Therapeutics Limited, renamed November 2025; ASX: ENP, OTC: TYPTF) is an Australian clinical-stage company developing psilocin-based therapies for conditions with major unmet need including fibromyalgia, binge eating disorder, and IBS. Its two-pronged strategy uses TRP-8802 (oral psilocybin) to establish clinical proof-of-concept, then advances TRP-8803 (proprietary IV psilocin formulation) for precision dosing. Phase 2a fibromyalgia and BED trials showed strong results; the world's first IV psilocin neuropsychiatric trial (TRP-8803 in BED) dosed its first patient on December 1, 2025 at Swinburne University.
View stakeholder →Osmind
Scientific Advisor
Psychiatry technology and real-world evidence platform supporting interventional mental health care, including psychedelic-assisted therapy workflows and psilocybin outcomes initiatives.
View stakeholder →Entropy Neurodynamics
Public BiotechChair, Scientific Advisory Board
Entropy Neurodynamics Limited (formerly Tryptamine Therapeutics Limited, renamed November 2025; ASX: ENP, OTC: TYPTF) is an Australian clinical-stage company developing psilocin-based therapies for conditions with major unmet need including fibromyalgia, binge eating disorder, and IBS. Its two-pronged strategy uses TRP-8802 (oral psilocybin) to establish clinical proof-of-concept, then advances TRP-8803 (proprietary IV psilocin formulation) for precision dosing. Phase 2a fibromyalgia and BED trials showed strong results; the world's first IV psilocin neuropsychiatric trial (TRP-8803 in BED) dosed its first patient on December 1, 2025 at Swinburne University.
View stakeholder →Synthesis
Advisory Board
Synthesis is a legal psilocybin retreat company based in the Netherlands, offering 'Immersion' — a comprehensive 7-week program including a 5-day in-person psilocybin truffle ceremony retreat held at the New Eden venue 90 minutes from Amsterdam. Founded in 2018 and having supported over 1,100 individuals, Synthesis integrates modern science with contemplative wisdom traditions and has collaborated with the Psychedelic Research Group at Imperial College London.
View stakeholder →